678982-27-9Relevant articles and documents
New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties
Koltun, Dmitry O.,Marquart, Timothy A.,Shenk, Kevin D.,Elzein, Elfatih,Li, Yuan,Nguyen, Marie,Kerwar, Suresh,Zeng, Dewan,Chu, Nancy,Soohoo, Daniel,Hao, Jia,Maydanik, Victoria Y.,Lustig, David A.,Ng, Khing-Jow,Fraser, Heather,Zablocki, Jeffery A.
, p. 549 - 552 (2004)
New inhibitors of palmitoylCoA oxidation were synthesized based on a structurally novel lead, CVT-3501 (1). Investigation of structure-activity relationships was conducted with respect to potency of inhibition of cardiac mitochondrial palmitoylCoA oxidation and metabolic stability. Potent and metabolically stable analogues 33, 42, and 43 were evaluated in vitro for cytochrome P450 inhibition and potentially adverse electrophysiological effects. Compound 33 was also found to have favorable pharmacokinetic properties in rat.
UREA DERIVATIVES OF PIPERAZINES AND PIPERIDINES AS FATTY ACID OXIDATION INHIBITORS
-
Page/Page column 40, (2008/06/13)
Disclosed are novel piperazine derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable
Substituted heterocyclic compounds
-
, (2008/06/13)
Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes, and for increasing HDL plasma levels in mammals.
